The controlled and specific re-activation of endogenous tumor suppressors in cancer cells represents an important therapeutic strategy to block tumor growth and subsequent progression. Other than ectopic delivery of tumor suppressor-encoded cDNA, there are no therapeutic tools able to specifically re-activate tumor suppressor genes that are silenced in tumor cells. Herein, we describe a novel approach to specifically regulate dormant tumor suppressors in aggressive cancer cells. We have targeted the Mammary Serine Protease Inhibitor (maspin) (SERPINB5) tumor suppressor, which is silenced by transcriptional and aberrant promoter methylation in aggressive epithelial tumors. Maspin is a multifaceted protein, regulating tumor cell homeostasis through inhibition of cell growth, motility and invasion. We have constructed artificial transcription factors (ATFs) made of six zinc-finger (ZF) domains targeted against 18-base pair (bp) unique sequences in the maspin promoter. The ZFs were linked to the activator domain VP64 and delivered in breast tumor cells. We found that the designed ATFs specifically interact with their cognate targets in vitro with high affinity and selectivity. One ATF was able to re-activate maspin in cell lines that comprise a maspin promoter silenced by epigenetic mechanisms. Consistently, we found that this ATF was a powerful inducer of apoptosis and was able to knock down tumor cell invasion in vitro. Moreover, this ATF was able to suppress MDA-MB-231 growth in a xenograft breast cancer model in nude mice. Our work suggests that ATFs could be used in cancer therapeutics as novel molecular switches to re-activate dormant tumor suppressors.
The controlled and specific re-activation of endogenous tumor suppressors in cancer cells represents an important therapeutic strategy to block tumor growth and subsequent progression. Other than ectopic delivery of tumor suppressor-encoded cDNA, there are no therapeutic tools able to specifically re-activate tumor suppressor genes that are silenced in tumor cells. Herein, we describe a novel approach to specifically regulate dormant tumor suppressors in aggressive cancer cells. We have targeted the Mammary Serine Protease Inhibitor (maspin) (SERPINB5) tumor suppressor, which is silenced by transcriptional and aberrant promoter methylation in aggressive epithelial tumors. Maspin is a multifaceted protein, regulating tumor cell homeostasis through inhibition of cell growth, motility and invasion. We have constructed artificial transcription factors (ATFs) made of six zinc-finger (ZF) domains targeted against 18-base pair (bp) unique sequences in the maspin promoter. The ZFs were linked to the activator domain VP64 and delivered in breast tumor cells. We found that the designed ATFs specifically interact with their cognate targets in vitro with high affinity and selectivity. One ATF was able to re-activate maspin in cell lines that comprise a maspin promoter silenced by epigenetic mechanisms. Consistently, we found that this ATF was a powerful inducer of apoptosis and was able to knock down tumor cell invasion in vitro. Moreover, this ATF was able to suppress MDA-MB-231 growth in a xenograft breast cancer model in nude mice. Our work suggests that ATFs could be used in cancer therapeutics as novel molecular switches to re-activate dormant tumor suppressors. Keywords: maspin; SERPINB5; metastatic cells; methylation; zinc-fingers; artificial transcription factors Tumor progression is a dynamic process controlled by multiple genetic factors, including oncogenes, which facilitate tumor growth, and tumor suppressors, which negatively regulate tumor growth and progression. Since the discovery of the tumor suppressor p53, more than 15 different tumor suppressor genes have been identified (Sherr, 2003; McGarvey et al., 2006) . The expression of tumor suppressors is downregulated in tumor cells by means of genetic and epigenetic mechanisms (Baylin, 2005; Zardo et al., 2005) . Given the importance of tumor suppressors in controlling primary tumor growth, many therapeutic strategies aim to restore their expression in tumor cells. Tumor suppressors silenced by methylation and transcriptional repression can be re-activated by a variety of chromatin remodeling drugs, such as methyltransferase inhibitors (including 5-aza-2 0 -deoxycytidine, recently approved for therapeutic treatment (Samlowski et al., 2005) and histone deacetylase inhibitors (such as suberoylanide hydroxamic acid (SAHA)). These drugs are able to relax the chromatin enhancing the accessibility of the transcription machinery (Garber, 2004) . However, potential limitations for the use of these drugs in cancer patients include their toxicity, lack of target specificity and development of acquired drug resistance (Juttermann et al., 1994) . In this paper, we describe a novel approach to specifically activate tumor suppressors that are epigenetically silenced in tumor cells. We hypothesized that artificial transcription factors (ATFs) designed to recognize specific sequences in the promoter of a tumor suppressor would result in a re-activation of the endogenous gene in tumor cells. In order to test this, we have chosen the tumor suppressor SERPINB5, or Mammary Serine Protease Inhibitor (maspin), as a prototype of a tumor suppressor gene (Zhou et al., 1994) silenced by epigenetic mechanisms in aggressive tumor cells. The choice of this target was based on the following characteristics: (1) maspin is not mutated or rearranged in tumor cells, but the gene is silenced during metastatic progression. This offers a unique opportunity for therapeutic intervention through specific re-activation of the endogenous gene. Maspin silencing involves: (1) transcriptional regulation (by means of TFs such as p53 (Zhou et al., 2000) , ETS, AP-1 (Zhang et al., 1997) , hormone receptor (Zhang et al., 1997; Khalkhali-Ellis et al., 2004) and aberrant promoter methylation (Domann et al., 2000; Futscher et al., 2002) . (2) High levels of maspin are associated not only with reduction of tumor growth , but also decreased angiogenesis (Zhang et al., 2000a) , cell motility and invasion (Sheng et al., 1996; Seftor et al., 1998) , and metastatic dissemination (Zhang et al., 2000b; Shi et al., 2002; Cher et al., 2003; Watanabe et al., 2005) . Maspinmediated reduction of tumor cell growth is at least partially attributed to enhancement of apoptosis Zhang et al., 2005) , whereas downregulation of cell invasion is associated with the inhibition of the activity of cell-surface-associated urokinase-type plasminogen activator Yin et al., 2006) . (3) Maspin is clinically relevant for several types of human cancers: breast, prostate, colon and squamous carcinomas. For these tumors, maspin expression is a predictor of better prognosis .
Results and discussion
In order to upregulate specifically the maspin promoter in breast cancer cell lines, we have designed ATFs made of six zinc-finger (6ZF) domains linked to the VP64 activator domain. Each ZF domain specifically recognizes 3 base pairs (bps) of DNA (Pavletich and Pabo, 1991) . Thus, a designed 6ZF ATF will recognize 18-bp, providing high degree of specificity (Blancafort et al., 2004; Beltran et al., 2006) . Indeed, previous reports have described that highly specific 6ZF ATFs are able to target unique sites in the human genome (Tan et al., 2003) . We chose three 18-bp sites in the maspin proximal promoter as targets for our ATFs (Figure 1a) . A BLAST-Search on the human genome has revealed that the three 18-bp targeted sites in the maspin promoter are unique (data not shown). Targets À126 and À97 were selected based on their close proximity to the transcription start site and because of the highly specific interactions predicted for the DNA triplets and the available ZF lexicons (Segal et al., 1999; Dreier et al., 2000 Dreier et al., , 2002 Dreier et al., , 2005 . In addition to the proximal ATF sites, we have designed an ATF recognizing an 18-bp site comprising the hormone response element (HRE) sequence, which interacts with the hormone receptor both in breast (Khalkhali-Ellis et al., 2004) and prostate (Zhang et al., 1997) cells. It has been shown that treatment of estrogen receptor (ER) þ breast cancer cells with the ER modulator Tamoxifen (TAM) results in the re-activation of maspin, and that this effect requires an intact HRE sequence (Khalkhali-Ellis et al., 2004) . Given the importance of HRE in regulating maspin, we reasoned that an ATF activator binding to a sequence comprising the HRE site could also lead to effective maspin transactivation.
The 6ZF DNA-binding domains (DBDs) designed to bind the 18-bp targets in the maspin promoter were built by overlapping PCR, by grafting the a-helical-coding sequences known to interact specifically with the targeted triplets ( Figure 1b ; Beerli et al., 1998) . To verify that the designed 6ZF DBDs were able to interact specifically with their cognate substrates, we first purified the ZFs as C-terminal fusion with the carrier maltose-binding protein (MBP) (Figure 1c ). Purified 6ZF-MBP fusions were next tested by a DNA-binding enzyme-linked immunosorbent (ELISA) assay to determine specificity and selectivity . We used several double-stranded oligonucleotide variants incorporating single and multiple nucleotide substitutions in the ZF binding sites to assess DNAbinding selectivity. As shown in Figure 1c , the 6ZF-DBDs bound their cognate substrates with high affinity, in the nano-and subnano-molar range. In addition, the designed DBDs appeared to be highly selective in vitro since nucleotide substitutions in the DNA-duplex substrate increased the relative dissociation constant (K d ). Single-nucleotide substitutions in all the 6ZF triplets increased the K d more than 100-fold ( Figure 1d ). Our results suggested that our designed DBDs bound their predicted substrates in vitro with sequence selectivity and in agreement with previous reports (Dreier et al., 2000) . However, more studies need to be performed to evaluate which degenerated DNA sequences could be bound by the ATFs in vivo.
To study if the designed 6ZF DBDs were able to transactivate the maspin promoter in breast cancer cells, we first performed reporter assays. The 6ZF DBDs were expressed as fusions with the powerful transcriptional regulator VP64, using a transient expression vector (pcDNA3.1; Blancafort et al., 2003) . Breast monocyte chemoattractant factor (MCF)-7 cells were co-transfected with the ATF expression vectors and with a reporter vector comprising the luciferase gene driven by the proximal 527-bp maspin promoter comprising all the 6ZF binding sites and two p53 binding sites (Zhou et al., 2000) . Consistent with previous reports, we found that Figure 1 The designed ATFs are able to bind specifically to their cognate 18-bp sequence and to activate the maspin promoter. (a) Binding sites for the three designed ATFs in the proximal maspin promoter. Numbers designate the distance in bps relative to the start of translation (first ATG codon, þ 1). Some of the response elements for known transcription factors are indicated. (b) a-Helical ZF sequences engineered to bind their corresponding target DNA triplets. These ZF sequences were chosen based on the available specific ZF lexicons (Segal et al., 1999; Dreier et al., 2000 Dreier et al., , 2001 Dreier et al., , 2005 . The 6ZF ATFs were constructed by overlapping PCR; Supplementary methods). (c) The designed ATFs are able to bind specifically to their cognate 18-bp substrate, as assessed by DNAbinding ELISA (Segal et al., 2003; Supplementary methods) . The ZF DBDs were expressed as C-terminal fusions with MBP (NEB, Ipswich, MA, USA). These fusions were more than 90% pure as assessed by SDS-PAGE (right panel). (d) Relative dissociation constant (K d ) of each protein for their cognate substrate and for different site-directed mutant substrates. An ELISA assay was used to calculate the relative K d using as standard control ATF 30 (a 6ZF protein of a known K d as described ). 
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Re-activation of a dormant tumor suppressor gene maspin A Beltran et al not result in significant reporter upregulation. The higher transactivation observed for ATF-97 could be explained by its close proximity to the transcription start site, facilitating the recruitment of the polymerase II complex (Stege et al., 2002) . To study if the designed ATFs were able to upregulate endogenous maspin in breast cancer cell lines, we expressed the ATFs using the retroviral vector pMX-IRES-GFP (Royer et al., 2004) , which allows the tracking of transduced cells by flow cytometry. All cell lines were efficiently transduced by the three ATFs, as assessed by flow cytometry (data not shown). Effective ATF expression was also verified by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), using ZF-specific primers for the detection (Figure 2 ). To evaluate Maspin expression, transduced cells were processed by Western blotting, using a wellcharacterized anti-Maspin monoclonal antibody for the detection ( Re-activation of a dormant tumor suppressor gene maspin A Beltran et al performed real-time expression analysis. We first delivered the ATFs in the MDA-MB-468 cell line, an ERÀ, poorly invasive, breast cancer cell line, which express maspin and comprises a non-methylated maspin promoter (Oshiro et al., 2003) . In this cell line, ATF-97, ATF-126 and ATF-452 were able to upregulate endogenous Maspin (3.3-, 5.4-and 2.3-fold, respectively) relative to controls (cells transduced with empty retroviral vectors, which express Green Flourescent Protein (GFP); Figure 2a-c) . This upregulation was specific as the deletion of the VP64 activator domain, the delivery of ATFs with different DNA-binding specificity or the delivery of a scramble of 6ZF ATF activator library (10 8 members; Blancafort et al., 2003) did not result in any detectable maspin regulation (Figure 2j-k) . Interestingly, the ATF with stronger activity in vivo (ATF-97) was not the stronger activator in the reporter assay. This result suggests that the structure of the chromatin could play a role in ATFmediated regulation of the endogenous gene. Consistent to this, we found that ATF-mediated regulation depended on the cell line analysed. In the MDA-MB-231 cell line, an aggressive cell ERÀ breast cancer cell line, which comprises a methylated and silenced maspin promoter, ATF-126 was able to strongly re-activate the promoter (70-fold relative to controls), whereas that ATF-97 and ATF-452 had a weak but significant activity (2.95 and 1.93, respectively). Control MDA-MB-231 cells did not express any detectable endogenous Maspin, which was consistent with the reported epigenetic silencing of the promoter in these cells (Figure  2d-f) . Importantly, ATF-126 was able to re-activate maspin at levels comparable to the MDA-MB-468 cell line, which comprises a non-methylated promoter (Figure 2j) . Finally, the ATFs were delivered in the ER þ , non-invasive MCF-7 cell line, which comprises a maspin promoter silenced by methylation and transcriptional regulation. In this cell line, maspin was upregulated by ATF-97 (3.1-fold) and ATF-126 (6.9-fold), compared to controls, whereas ATF-452 had a weak but significant effect (Figure 2g-i) . The weak but significant endogenous activity of ATF-452 in both ERÀ and ER þ cell lines could be explained by the fact that this ATF targets an upstream site, which is either unaccessible or too far from the transcription start site to elicit efficient recruitment of the transcription machinery. These experiments demonstrated that ATFs could be used to re-activate endogenous tumor suppressors silenced by epigenetic mechanisms. Consistent to our results, it has been shown that ectopic expression of p53 in the p53-deficient MDA-MB-231 also results in a partial re-activation of the endogenous gene (Oshiro et al., 2003) . p53 expression did not alter the methylation status of the maspin promoter, but rather increased acetylation levels and maspin promoter accessibility, thereby facilitating transcription. Similarly, we could speculate that ATFs could also enhance histone acetylation levels through the VP64 activator domain, resulting in increased chromatin accessibility and enhanced transcription. This is presently being investigated in our laboratory.
We subsequently analysed the functional and phenotypic properties of breast cancer cells transduced with our designed ATFs. As ectopic expression of maspin cDNA in breast cancer cells leads to enhancement of apoptosis and decreased cell motility and invasion , we then studied if the designed ATFs also induced similar phenotypic alterations. To study quantitatively the fraction of apoptotic cells, we performed Annexin-V flow cytometry analysis of cells transduced with our designed ATFs, control cells (transduced with empty retroviral vectors which express GFP) and un-transduced cells. As shown in Figure 3a , ATF-126 and ATF-97 were both able to induce apoptosis in the MDA-MB-468 cell line (55 and 25%, respectively). As expected from its low activity in regulating maspin, ATF-452 had no significant induction of apoptosis in this cell line, relative to control (11.8%). In the MDA-MB-231 cell line, only ATF-126 was able to strongly induce apoptosis (70%), whereas ATF-97 and ATF-452 had no significant effect (12 and 24%, respectively) ( Figure 3c ). Consistent with the capability of and to induce apoptosis in breast cancer cell lines, we found that these ATFs were able to decrease breast tumor cell proliferation relative to controls (Figure 3a and c, right plots) . The differential effect of the ATFs in inducing apoptosis in the two breast cell lines is consistent with the levels of maspin upregulation (Figure 2) .
To study if the designed ATFs were able to knock down breast cancer cell invasion in vitro, we performed Matrigel invasion assays. As expected from their capability to upregulate maspin expression, ATF-97, ATF-126 and ATF-452 were able to knock down cell invasion in the MDA-MB-468 background (37.5, 66.4 and 27.6%, respectively, relative to controls; Figure 3b) . Similarly, in the highly invasive MDA-MB-231 cells line, the three ATFs were able to knock down cell invasion (31.5, 77.4 and 44.7%, respectively, relative to controls) (Figure 3d ).
To study if ATF-126 was also able to reduce tumor growth in vivo, we transduced the aggressive MDA-MB-231-luc cell line (which stably expresses the reporter luciferase) with ATF-126 and with an empty retroviral vector (control). A total of 10 6 transduced cells were injected subcutaneously into the flank of immunodeficient mice (N ¼ 6). Tumor growth in both groups (ATFtransduced and controls) was monitored both by caliper measurements and also by Bioluminiscence Imaging (by non-invasive in vivo monitoring of luciferase activity in these mice; Minn et al., 2005) . As shown in Figure 4 , mice injected with control cells all developed primary tumors, whereas none of the mice injected with ATF-126-expressing cells generated tumors. These data demonstrated that ATF-126 was able to suppress xenograft growth of the MDA-MB-231 cell line in SCID mice.
In summary, our data demonstrate that ATFs can be used to specifically re-activate tumor suppressors that are silenced in metastatic breast tumor cell lines. Although additional work needs to be performed to evaluate how this ATF exerts its mechanism of action (e.g., if the ATF alters methylation, acetylation status and chromatin accessibility), our work suggests that ATFs could be used in cancer therapeutics as novel strategic intervention to downregulate tumor growth. Given the clinical relevance of maspin expression in a variety of epithelial tumors (including breast, prostate, lung and colon), our work describes a novel approach to target multiple human neoplasias.
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